Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.
Esophageal Squamous Cell Carcinoma
DRUG: Nivolumab
Major pathologic response, Viable tumor comprised â‰¤ 10% of resected tumor specimens, 2 months
Objective response rate (ORR), Partial response is defined as a decrease by 30% or more in sums of longest diameter of measurable target lesions, 2 months|Positron Emission Tomography (PET)-CT response, Complete metabolic response is defined as the SUV of 2.5 or less than 2.5 of primary tumor, 2 months|Progression-free survival (PFS), Time from the enrollment to disease relapse after complete resection or death from any cause, 24 months|Overall survival (OS), Time from the enrollment to death of any cause, 24 months
This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.